within Pharmacolibrary.Drugs.ATC.R;

model R03AL12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 25.166666666666668,
    adminDuration  = 600,
    adminMass      = 0.15,
    adminCount     = 1,
    Vd             = 2.38,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Indacaterol, glycopyrronium bromide, and mometasone is a fixed-dose combination inhalation medication used for maintenance treatment of asthma in adults, containing an ultra-long-acting beta2-agonist (indacaterol), a long-acting muscarinic antagonist (glycopyrronium bromide), and an inhaled corticosteroid (mometasone furoate). It is approved for use in several countries for regular treatment of asthma where combination therapy is appropriate.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for the fixed-dose triple combination (indacaterol, glycopyrronium, and mometasone furoate) in adult asthmatic patients, following once-daily inhaled administration via Breezhaler.</p><h4>References</h4><ol><li><p>Vaidya, S, et al., &amp; Tillmann, HC (2020). Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. <i>Pulmonary pharmacology &amp; therapeutics</i> 64 101964–None. DOI:<a href=&quot;https://doi.org/10.1016/j.pupt.2020.101964&quot;>10.1016/j.pupt.2020.101964</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33035700/&quot;>https://pubmed.ncbi.nlm.nih.gov/33035700</a></p></li><li><p>Inoue, S, et al., &amp; Furihata, K (2021). Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects. <i>BMC pulmonary medicine</i> 21(1) 18–None. DOI:<a href=&quot;https://doi.org/10.1186/s12890-020-01382-6&quot;>10.1186/s12890-020-01382-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33413291/&quot;>https://pubmed.ncbi.nlm.nih.gov/33413291</a></p></li><li><p>Bartels, C, et al., &amp; Vaidya, S (2021). Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler. <i>European journal of drug metabolism and pharmacokinetics</i> 46(4) 487–504. DOI:<a href=&quot;https://doi.org/10.1007/s13318-021-00689-x&quot;>10.1007/s13318-021-00689-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34024035/&quot;>https://pubmed.ncbi.nlm.nih.gov/34024035</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03AL12;
